Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer
- PMID: 22831985
- PMCID: PMC3457750
- DOI: 10.1093/annonc/mds210
Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer
Abstract
Background: Approximately 25% of patients with esophageal cancer (EC) who undergo preoperative chemoradiation, achieve a pathologic complete response (pathCR). We hypothesized that a model based on clinical parameters could predict pathCR with a high (≥60%) probability.
Patients and methods: We analyzed 322 patients with EC who underwent preoperative chemoradiation. All the patients had baseline and postchemoradiation positron emission tomography (PET) and pre- and postchemoradiation endoscopic biopsy. Logistic regression models were used for analysis, and cross-validation via the bootstrap method was carried out to test the model.
Results: The 70 (21.7%) patients who achieved a pathCR lived longer (median overall survival [OS], 79.76 months) than the 252 patients who did not achieve a pathCR (median OS, 39.73 months; OS, P = 0.004; disease-free survival, P = 0.003). In a logistic regression analysis, the following parameters contributed to the prediction model: postchemoradiation PET, postchemoradiation biopsy, sex, histologic tumor grade, and baseline (EUS)T stage. The area under the receiver-operating characteristic curve was 0.72 (95% confidence interval [CI] 0.662-0.787); after the bootstrap validation with 200 repetitions, the bias-corrected AU-ROC was 0.70 (95% CI 0.643-0.728).
Conclusion: Our data suggest that the logistic regression model can predict pathCR with a high probability. This clinical model could complement others (biomarkers) to predict pathCR.
Figures
Similar articles
-
The Incremental Value of Subjective and Quantitative Assessment of 18F-FDG PET for the Prediction of Pathologic Complete Response to Preoperative Chemoradiotherapy in Esophageal Cancer.J Nucl Med. 2016 May;57(5):691-700. doi: 10.2967/jnumed.115.163766. Epub 2016 Jan 21. J Nucl Med. 2016. PMID: 26795288
-
Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort.Ann Oncol. 2013 May;24(5):1262-6. doi: 10.1093/annonc/mds617. Epub 2012 Dec 17. Ann Oncol. 2013. PMID: 23247658 Free PMC article.
-
Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response.Cancer. 2005 Dec 1;104(11):2365-72. doi: 10.1002/cncr.21439. Cancer. 2005. PMID: 16245310
-
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.Ann Thorac Surg. 2004 Oct;78(4):1152-60; discussion 1152-60. doi: 10.1016/j.athoracsur.2004.04.046. Ann Thorac Surg. 2004. PMID: 15464463 Review.
-
Preoperative concurrent chemotherapy and radiation therapy followed by surgery for esophageal cancer.Ann Thorac Cardiovasc Surg. 2002 Jun;8(3):123-30. Ann Thorac Cardiovasc Surg. 2002. PMID: 12472392 Review.
Cited by
-
A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer.J Gastrointest Oncol. 2015 Feb;6(1):45-52. doi: 10.3978/j.issn.2078-6891.2014.054. J Gastrointest Oncol. 2015. PMID: 25642337 Free PMC article.
-
Nomogram for Predicting Pathologic Response Following Neoadjuvant Chemotherapy or Chemoradiotherapy in Patients with Esophageal Cancer.Ann Surg Oncol. 2023 Apr;30(4):1945-1947. doi: 10.1245/s10434-023-13133-y. Epub 2023 Jan 30. Ann Surg Oncol. 2023. PMID: 36715858 No abstract available.
-
Non responders to neoadjuvant chemoradiation for esophageal cancer: why better prediction is necessary.J Thorac Dis. 2017 Jul;9(Suppl 8):S843-S850. doi: 10.21037/jtd.2017.06.123. J Thorac Dis. 2017. PMID: 28815082 Free PMC article.
-
Signet Ring Cell Features are Associated with Poor Response to Neoadjuvant Treatment and Dismal Survival in Patients with High-Grade Esophageal Adenocarcinoma.Ann Surg Oncol. 2021 Sep;28(9):4929-4940. doi: 10.1245/s10434-021-09644-1. Epub 2021 Mar 11. Ann Surg Oncol. 2021. PMID: 33709175
-
Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients.Br J Cancer. 2017 Aug 22;117(5):648-655. doi: 10.1038/bjc.2017.225. Epub 2017 Jul 20. Br J Cancer. 2017. PMID: 28728163 Free PMC article.
References
-
- Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108. - PubMed
-
- Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010 doi:10.1002/ijc.25516. - DOI - PubMed
-
- Cancer Research UK. Oesophageal (gullet) cancer. [on-line] 2008 http://info.cancerresearchuk.org/cancerstats/types/oesophagus/incidence/ (14 October 2008, date last accessed)
-
- Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100(16):1184–1187. doi:10.1093/jnci/djn211. - DOI - PMC - PubMed
-
- Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97(2):142–146. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases